Sven Francque and William Alazawi join the Surfers discuss the impact of concomitant metabolic therapies like incretin agonists on MASH Drug Development.
Sven Francque and William Alazawi join the Surfers to discuss challenges in creating efficacy endpoints, and also areas where development has improved since 2020during MASH Drug Development.
Sven Francque and William Alazawi join the Surfers to discuss challenges in proper scoring and categorization of efficacy endpoints during MASH Drug Development.
Sven Francque joins guest William Alazawi and the Surfers to discuss high points from his 2023 article on the MASH drug development graveyard in 2023
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
This final conversation touches on prescribing models and the increasing challenge keeping patients in long-term clinical trials, after which Roger Green asks a final question.
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hannes Hagstrom and the Surfers consider how the need for predictive biomarkers will co-evolve with in-office screening as multiple drugs come to market.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
